Classification Moxifloxacin is a 4th generation fluoroquinolone. 1st generation – Cinoxacin, nalidixic acid, and oxolinic acid 2nd generation – Ciprofloxacin, enoxacin, lomefloxacin, ofloxacin and norfloxacin. 3rd generation – Grepafloxacin, levofloxacin, and sparfloxacin 4th generation – Cinafloxacin, gatifloxacin, moxifloxacin &
MOXI Each film-coated MOXI tablet – contains Moxifloxacin Hydrochloride equivalent to Moxifloxacin = 400 mg. – is indicated for the treatment of adults with upper and lower respiratory tract, skin/skin structure, and intra-abdominal infections. – safety and tolerability summarized from meta-analysis in over 4300 patients. – exerts its action by inhibiting the bacterial topoisomerases II (DNA gyrase) and topoisomerases IV which interferes with bacterial DNA replication, transcription, repair, and recombination.
Moxi- What? Moxifloxacin has a high activity against most respiratory pathogens. Moxifloxacin has been shown to be effective against Gram+ve, Gram-ve, and atypical strains, as well as multi-drug resistant Streptococcus pneumoniae. Moxifloxacin is effective in controlled studies of – community-acquired pneumonia, – exacerbations of chronic bronchitis and – acute bacterial rhinosinusitis. Expert Opinion on Pharmacotherapy, July 2008, Vol. 9, No. 10 , Pages 1755-1772
MOXI - Why? In cases of acute exacerbations of chronic bronchitis (AECB) and community-acquired pneumonia (CAP), recent guidelines suggest using fluoroquinolone antibiotics as first- line therapy. This suggestion is based evidence from several trials that show: – Clinical superiority – Microbial superiority. – Shorter hospital stay, – Reduced recurrences, and – Lower costs. Fortunately, resistance to these agents is still very low, and reserving them for use in populations at risk should preserve their effectiveness for some time
MOXI - Benefits Moxifloxacin has 1. A long elimination half-life that permits once-daily dosing. 2. Excellent pharmacokinetic profile characterized by respiratory tissue concentrations in upper and lower respiratory tissues that significantly exceed serum levels, 3. Excellent pharmacodynamic profile implies that the drug can achieve high response rates with shorter courses of therapy while minimizing the development of resistance.
MOXI - Benefits Moxifloxacin has 1. A postantibiotic effect is observed for both gram- positive and gram-negative bacteria. 1. Balanced system of excretion & so no dosage adjustments are required in patients with renal or hepatic impairment. 2. No clinically significant drug interactions due to lack of inhibition or stimulation of hepatic metabolism.
MOXI - Outcomes In this era of emerging resistance of community-acquired respiratory pathogens to cephalosporins and other beta- lactams, macrolides, and tetracycline is common. – Moxifloxacin has excellent in vitro inhibitory activity against antibiotic-resistant S. pneumoniae, beta-lactamase-producing Haemophilus sp, and M. catarrhalis, as well as atypical organisms. – Emergence of resistance to moxifloxacin is still uncommon, including selection of resistance under experimental conditions (methicillin-sensitive Staphylococcus aureus, S. pneumoniae).
MOXI - Side effects Low photosensitizing potential. Negligible sude effects profile Common side effects include: – Nausea, – Vomiting – Dizziness
MOXI - Summary of trials Moxifloxacin compared to other fluoroquinolone antibiotics: – significant improvement in the rate of “clinical recovery” (defined as the resolution of or reduction in acute signs and symptoms of infection) in patients receiving moxifloxacin after 3 to 5 days of therapy Moxifloxacin compared to other classes of antibiotic drugs Moxifloxacin in SSTI – Clinical cure/improvement rates at 7–21d after the end of therapy were around 90%.
MOXI - Summary of studies Moxifloxacin has demonstrated a faster resolution of symptoms in community-acquired pneumonia and exacerbations of chronic bronchitis patients compared with first-line therapy together with excellent eradication rates. The use of moxifloxacin as first-line therapy for moderate to severe respiratory infections in the community and the hospital has been